AIP
ABCL icon

Ameritas Investment Partners’s AbCellera Biologics ABCL Stock Holding History

Ameritas Investment Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,571
Closed -$125K – 3107
2023
Q1 		$125K Hold
16,571
– – ﹤0.01% 1388
2022
Q4 		$170K Buy
16,571
+1,039
+7% +$12K 0.01% 1245
2022
Q3 		$153K Hold
15,532
– – 0.01% 1204
2022
Q2 		$165K Buy
+15,532
New +$132K 0.01% 1183

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Ameritas Investment Partners's ABCL Position: Q2 2023 in Review

Ameritas Investment Partners sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 16,571 shares — an estimated $125K sold.

Ameritas Investment Partners first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $170K in Q4 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Ameritas Investment Partners reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Ameritas Investment Partners sold 16,571 AbCellera Biologics shares in Q2 2023, an estimated $125K.
  • Ameritas Investment Partners first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • Ameritas Investment Partners's AbCellera Biologics position peaked at $170K in Q4 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.